Celldex Therapeutics, Inc. financial data

Symbol
CLDX on Nasdaq
Location
Hampton, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1785% % -26.8%
Debt-to-equity 6.25% % 31.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66,449,471 shares 0.16%
Common Stock, Shares, Outstanding 66,446,846 shares 0.16%
Entity Public Float $2,400,000,000 USD 50%
Common Stock, Value, Issued $66,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 66,420 shares 0.19%
Weighted Average Number of Shares Outstanding, Diluted 66,420 shares 0.19%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $5,791,000 USD -30.2%
Research and Development Expense $216,680,000 USD 47.4%
General and Administrative Expense $42,160,000 USD 13.6%
Costs and Expenses $258,840,000 USD 31.6%
Operating Income (Loss) $-256,240,000 USD -37.3%
Net Income (Loss) Attributable to Parent $-67,044,000 USD -59.2%
Earnings Per Share, Basic -3 USD/shares -31%
Earnings Per Share, Diluted -3 USD/shares -31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $36,037,000 USD -1%
Marketable Securities, Current $547,186,000 USD -24%
Assets, Current $604,339,000 USD -22.4%
Property, Plant and Equipment, Net $4,829,000 USD 14.2%
Operating Lease, Right-of-Use Asset $2,717,000 USD -14.3%
Intangible Assets, Net (Excluding Goodwill) $27,190,000 USD 0%
Other Assets, Noncurrent $9,364,000 USD -3.93%
Assets $648,439,000 USD -21.2%
Accounts Payable, Current $4,267,000 USD 283%
Employee-related Liabilities, Current $11,568,000 USD 23.7%
Accrued Liabilities, Current $39,715,000 USD 40.8%
Liabilities, Current $46,465,000 USD 44.8%
Operating Lease, Liability, Noncurrent $1,068,000 USD -37.5%
Other Liabilities, Noncurrent $2,543,000 USD -26.8%
Liabilities $50,076,000 USD 34.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $3,765,000 USD -28.8%
Retained Earnings (Accumulated Deficit) $-1,732,664,000 USD -14.9%
Stockholders' Equity Attributable to Parent $598,363,000 USD -23.9%
Liabilities and Equity $648,439,000 USD -21.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-54,372,000 USD -33.8%
Net Cash Provided by (Used in) Financing Activities $202,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $42,950,000 USD
Common Stock, Shares Authorized 297,000,000 shares 0%
Common Stock, Shares, Issued 66,446,846 shares 0.16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $-11,220,000 USD -114%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36,037,000 USD -1%
Deferred Tax Assets, Valuation Allowance $319,756,000 USD -7.95%
Deferred Tax Assets, Gross $324,983,000 USD -7.84%
Operating Lease, Liability $3,813,000 USD 50%
Payments to Acquire Property, Plant, and Equipment $265,000 USD -23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $-226,055,000 USD -49.8%
Lessee, Operating Lease, Liability, to be Paid $4,282,000 USD 56.4%
Property, Plant and Equipment, Gross $27,810,000 USD 5.16%
Operating Lease, Liability, Current $1,553,000 USD 12.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,779,000 USD 87.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,761,000 USD -1.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $469,000 USD 141%
Lessee, Operating Lease, Liability, to be Paid, Year Three $742,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $176,816,000 USD -10.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $867,000 USD 11.9%
Share-based Payment Arrangement, Expense $37,088,000 USD 17.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%